Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Update on overall survival in ARCHES trial

Andrew Armstrong • 17 Sep 2021
ESMO 2021
Genitourinary Cancer Prostate Cancer Docetaxel Enzalutamide
ARCHES ENZAMET

Andrew J. Amstrong, MD, Duke Cancer Institute, Durham, NC, gives an update on the overall survival results for the ARCHES trial (NCT02677896), which looked at enzalutamide, an androgen receptor (AR) inhibitor, in combination with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer. The updated overall survival results are highly promising, with a greater probability of delaying the symptomatic and radiographic progression of disease. Prof. Armstrong compares these results with those of ENZAMET (NCT02446405) for this patient type. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr Armstrong reports research support (to Duke) from the NIH/NCI, PCF/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, Dendreon, Genentech/Roche, BMS, AstraZeneca, Merck, Constellation, Beigene, Forma, Celgene, Amgen.

Dr Armstrong reports consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Clovis, Exact Sciences

More from Andrew Armstrong

Key prostate cancer trials at ASCO 2026: PROTEUS, TALAPRO-3, and A-DREAM
5:41
Key prostate cancer trials at ASCO 2026: PROTEUS, TALAPRO-3, and A-DREAM
Andrew Armstrong • 3 Jun 2026
Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
2:19
Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals